A number of rare/genetic disease readouts are set this Q3 2025. Some of them are likely to move big. See table below for 6 of the anticipated readouts. 📈 📉 6 stocks likely to move big on rare/genetic disease readouts in Q3 ‘25 👇    $ARCT ARCT-032 / Cystic Fibrosis / Phase 2 » Safety findings → No SAEs, severe AEs, or dose-limiting toxicities → Dose-related increase in transient, mild, post-dose respiratory symptoms » PK findings: Very low systemic exposure → mRNA: all plas

A number of rare/genetic disease readouts are set this Q3 2025. Some of them are likely to move big. See table below for 6 of the anticipated readouts. 📈 📉

$XBI $88.87 | -0.78% Table of Contents: Top 10 Daily Positive Movers Top 10 Daily Negative Movers Top 10 Daily Volume Movers Want to...

$XBI $88.87 | -0.78% Table of Contents: Top 10 Daily Positive Movers Top 10 Daily Negative Movers Top 10 Daily Volume Movers Want to...

As we begin June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for...